

# Oncology and Cancer Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

https://marketpublishers.com/r/O6C2E92E9D9EEN.html

Date: March 2025 Pages: 119 Price: US\$ 3,200.00 (Single User License) ID: O6C2E92E9D9EEN

# **Abstracts**

Oncology and Cancer Treatment Drug Market Summary Introduction

Oncology and cancer treatment drugs encompass chemotherapy, targeted therapies, and immunotherapy, addressing cancers like breast, lung, and prostate. This dynamic market is propelled by rising cancer incidence, breakthroughs in biologics, and personalized medicine. High R&D costs, lengthy approval processes, and a shift toward combination therapies define the industry, which operates at the forefront of pharmaceutical innovation.

# Market Size and Growth Forecast

The global oncology drug market is valued at USD 180 billion to USD 200 billion in 2025, with a CAGR of 7.0% to 8.5% from 2025 to 2030, reaching USD 270 billion to USD 310 billion by 2030. Growth is fueled by innovation and increasing cancer prevalence.

# **Regional Analysis**

North America holds 40-45%, growing at 6.0-7.0%. The U.S. leads with advanced oncology care and immunotherapy adoption, while Canada follows with steady demand. Europe accounts for 25-30%, growing at 5.5-6.5%. Germany and the UK drive usage with robust healthcare, focusing on targeted therapies. Asia Pacific represents 20-25%, growing at 9.0-10.5%. China and India expand with rising cancer rates and generics, trending toward affordability. The Rest of the World holds 10-15%, growing at 7.5-8.5%, with Brazil emphasizing access.



#### **Application Analysis**

Breast cancer dominates with 20-25%, growing at 6.5-7.5%, driven by targeted therapies, with trends in early detection. Stomach cancer holds 10-15%, growing at 6.0-7.0%, focusing on chemotherapy. Ovarian cancer accounts for 5-10%, growing at 7.0-8.0%, with immunotherapy trends. Lung cancer represents 15-20%, growing at 7.5-8.5%, driven by targeted drugs. Testicular cancer holds 5-10%, growing at 6.0-7.0%, with niche applications. Cervical cancer accounts for 5-10%, growing at 6.5-7.5%, with prevention trends. Endometrial cancer holds 5-10%, growing at 6.0-7.0%, with targeted focus. Prostate cancer represents 10-15%, growing at 7.0-8.0%, with immunotherapy growth. Bladder cancer accounts for 5-10%, growing at 6.5-7.5%, with emerging therapies. Others grow variably.

#### Product Type Analysis

Chemotherapy drugs hold 35-40%, growing at 5.5-6.5%, valued for broad use, with trends in generics. Targeted drugs account for 35-40%, growing at 7.5-8.5%, focusing on precision, with trends in biomarkers. Immunotherapy drugs represent 20-25%, growing at 9.0-10.5%, with trends in checkpoint inhibitors.

#### Key Market Players

Roche: A Swiss titan pioneering targeted and immunotherapy cancer solutions. Novartis: A Swiss leader advancing precision oncology drugs globally. Sanofi: A French powerhouse delivering innovative cancer therapies. Bayer: A German giant crafting robust oncology treatments. Merck: A U.S. innovator leading in immunotherapy advancements. Eli Lilly: A U.S. specialist enhancing cancer care with targeted drugs. Pfizer: A U.S. titan producing a wide range of oncology therapies. Johnson & Johnson: A U.S. leader integrating oncology into its portfolio. Astellas: A Japanese firm advancing cancer treatment innovations. AbbVie: A U.S. specialist delivering cutting-edge oncology drugs. Teva: An Israeli giant supplying affordable cancer generics. Otsuka: A Japanese innovator crafting niche oncology solutions. Amgen: A U.S. biotech leader advancing immunotherapy drugs. Yi Bai Pharmaceutical: A Chinese expert producing oncology treatments for Asia. Qilu Pharmaceutical: A Chinese titan offering cost-effective cancer drugs. Sun Pharma: An Indian powerhouse delivering affordable oncology generics. Accord Healthcare: A UK innovator supplying oncology solutions globally. GSK: A British leader advancing cancer treatment portfolios. Bristol-Myers Squibb: A U.S. titan pioneering immunotherapy breakthroughs.



Takeda: A Japanese firm enhancing oncology care worldwide. Eisai: A Japanese specialist crafting innovative cancer therapies. Biogen Idec: A U.S. leader exploring oncology applications. Viatris: A U.S.-based firm offering a broad oncology generic range.

## Porter's Five Forces Analysis

Threat of New Entrants: Low to Medium. High R&D costs, lengthy clinical trials, and regulatory hurdles deter new players, though generics and biosimilars lower barriers for established firms in high-growth regions like Asia.

Threat of Substitutes: Medium. Alternative treatments like surgery or radiation compete, but oncology drugs' efficacy in advanced stages and combination potential maintain their critical role in treatment protocols.

Bargaining Power of Buyers: High. Governments, hospitals, and insurers demand costeffective therapies, leveraging bulk purchasing and reimbursement negotiations to influence pricing and access terms significantly.

Bargaining Power of Suppliers: Medium. Specialized raw materials and biotech inputs give suppliers some leverage, though large players mitigate this through vertical integration and diversified sourcing strategies.

Competitive Rivalry: High. A dynamic mix of global giants and regional generic producers fuels fierce competition, with differentiation driven by innovation, pricing, and market penetration across diverse cancer types and regions.

#### Market Opportunities and Challenges

#### Opportunities

Cancer incidence rise: Escalating global cancer rates, particularly in lung and breast cancers, drive demand for oncology drugs, creating a robust market for innovative and generic therapies alike.

Immunotherapy boom: Rapid advancements in checkpoint inhibitors and CAR-T therapies fuel growth, positioning oncology drugs at the forefront of transformative cancer care strategies.

Emerging market expansion: Increasing healthcare investments in China and India amplify access to affordable generics, tapping into vast patient pools with rising treatment needs.

Personalized medicine growth: Biomarker-driven targeted therapies enhance efficacy, opening new avenues for tailored treatments and strengthening oncology's role in precision healthcare.

#### Challenges

High R&D costs: Developing new oncology drugs demands billions and years of investment, straining budgets and risking financial losses if trials fail or approvals falter.



Generic pricing pressure: Patent expirations and generic competition erode branded drug margins, challenging profitability in a market increasingly driven by cost containment.

Regulatory complexity: Diverse global standards for oncology drugs delay market entry, increasing compliance costs and complicating supply chains across regions.

Toxicity and resistance: Side effects and tumor resistance limit drug effectiveness, pushing manufacturers to innovate continuously or risk losing share to safer, more durable alternatives.



# Contents

#### **CHAPTER 1 EXECUTIVE SUMMARY**

#### **CHAPTER 2 ABBREVIATION AND ACRONYMS**

## **CHAPTER 3 PREFACE**

- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users

#### CHAPTER 5 MARKET TREND ANALYSIS

- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats

#### **CHAPTER 6 INDUSTRY CHAIN ANALYSIS**

- 6.1 Upstream/Suppliers Analysis
- 6.2 Oncology and Cancer Treatment Drug Analysis
  - 6.2.1 Technology Analysis
  - 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users

# **CHAPTER 7 LATEST MARKET DYNAMICS**

- 7.1 Latest News
- 7.2 Merger and Acquisition

Oncology and Cancer Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Parti...



7.3 Planned/Future Project

# 7.4 Policy Dynamics

# CHAPTER 8 HISTORICAL AND FORECAST ONCOLOGY AND CANCER TREATMENT DRUG MARKET IN NORTH AMERICA (2020-2030)

- 8.1 Oncology and Cancer Treatment Drug Market Size
- 8.2 Oncology and Cancer Treatment Drug Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Oncology and Cancer Treatment Drug Market Size by Type
- 8.5 Key Countries Analysis
  - 8.5.1 United States
  - 8.5.2 Canada
  - 8.5.3 Mexico

# CHAPTER 9 HISTORICAL AND FORECAST ONCOLOGY AND CANCER TREATMENT DRUG MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 Oncology and Cancer Treatment Drug Market Size
- 9.2 Oncology and Cancer Treatment Drug Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Oncology and Cancer Treatment Drug Market Size by Type
- 9.5 Key Countries Analysis
  - 9.5.1 Brazil
  - 9.5.2 Argentina
  - 9.5.3 Chile
  - 9.5.4 Peru

# CHAPTER 10 HISTORICAL AND FORECAST ONCOLOGY AND CANCER TREATMENT DRUG MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 Oncology and Cancer Treatment Drug Market Size
- 10.2 Oncology and Cancer Treatment Drug Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Oncology and Cancer Treatment Drug Market Size by Type
- 10.5 Key Countries Analysis
  - 10.5.1 China
  - 10.5.2 India
  - 10.5.3 Japan



10.5.4 South Korea 10.5.5 Southest Asia 10.5.6 Australia

# CHAPTER 11 HISTORICAL AND FORECAST ONCOLOGY AND CANCER TREATMENT DRUG MARKET IN EUROPE (2020-2030)

- 11.1 Oncology and Cancer Treatment Drug Market Size
- 11.2 Oncology and Cancer Treatment Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Oncology and Cancer Treatment Drug Market Size by Type
- 11.5 Key Countries Analysis
  - 11.5.1 Germany
  - 11.5.2 France
  - 11.5.3 United Kingdom
  - 11.5.4 Italy
  - 11.5.5 Spain
  - 11.5.6 Belgium
  - 11.5.7 Netherlands
  - 11.5.8 Austria
  - 11.5.9 Poland
  - 11.5.10 Russia

# CHAPTER 12 HISTORICAL AND FORECAST ONCOLOGY AND CANCER TREATMENT DRUG MARKET IN MEA (2020-2030)

- 12.1 Oncology and Cancer Treatment Drug Market Size
- 12.2 Oncology and Cancer Treatment Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Oncology and Cancer Treatment Drug Market Size by Type
- 12.5 Key Countries Analysis
- 12.5.1 Egypt
- 12.5.2 Israel
- 12.5.3 South Africa
- 12.5.4 Gulf Cooperation Council Countries
- 12.5.5 Turkey

# CHAPTER 13 SUMMARY FOR GLOBAL ONCOLOGY AND CANCER TREATMENT DRUG MARKET (2020-2025)



#### 13.1 Oncology and Cancer Treatment Drug Market Size

- 13.2 Oncology and Cancer Treatment Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Oncology and Cancer Treatment Drug Market Size by Type

# CHAPTER 14 GLOBAL ONCOLOGY AND CANCER TREATMENT DRUG MARKET FORECAST (2025-2030)

- 14.1 Oncology and Cancer Treatment Drug Market Size Forecast
- 14.2 Oncology and Cancer Treatment Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Oncology and Cancer Treatment Drug Type Forecast

## CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 Roche
  - 15.1.1 Company Profile
  - 15.1.2 Main Business and Oncology and Cancer Treatment Drug Information
  - 15.1.3 SWOT Analysis of Roche
- 15.1.4 Roche Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.2 Novartis

- 15.2.1 Company Profile
- 15.2.2 Main Business and Oncology and Cancer Treatment Drug Information
- 15.2.3 SWOT Analysis of Novartis
- 15.2.4 Novartis Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.3 Sanofi

15.3.1 Company Profile

- 15.3.2 Main Business and Oncology and Cancer Treatment Drug Information
- 15.3.3 SWOT Analysis of Sanofi
- 15.3.4 Sanofi Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.4 Bayer

15.4.1 Company Profile

- 15.4.2 Main Business and Oncology and Cancer Treatment Drug Information
- 15.4.3 SWOT Analysis of Bayer
- 15.4.4 Bayer Oncology and Cancer Treatment Drug Revenue, Gross Margin and



Market Share (2020-2025)

15.5 Merck

15.5.1 Company Profile

15.5.2 Main Business and Oncology and Cancer Treatment Drug Information

15.5.3 SWOT Analysis of Merck

15.5.4 Merck Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.6 Eli Lilly

15.6.1 Company Profile

15.6.2 Main Business and Oncology and Cancer Treatment Drug Information

15.6.3 SWOT Analysis of Eli Lilly

15.6.4 Eli Lilly Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.7 Pfizer

15.7.1 Company Profile

15.7.2 Main Business and Oncology and Cancer Treatment Drug Information

15.7.3 SWOT Analysis of Pfizer

15.7.4 Pfizer Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.8 Johnson & Johnson

15.8.1 Company Profile

15.8.2 Main Business and Oncology and Cancer Treatment Drug Information

15.8.3 SWOT Analysis of Johnson & Johnson

15.8.4 Johnson & Johnson Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.9 Astellas

15.9.1 Company Profile

15.9.2 Main Business and Oncology and Cancer Treatment Drug Information

15.9.3 SWOT Analysis of Astellas

15.9.4 Astellas Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.10 AbbVie

15.10.1 Company Profile

15.10.2 Main Business and Oncology and Cancer Treatment Drug Information

15.10.3 SWOT Analysis of AbbVie

15.10.4 AbbVie Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.11 Teva

15.11.1 Company Profile



15.11.2 Main Business and Oncology and Cancer Treatment Drug Information

15.11.3 SWOT Analysis of Teva

15.11.4 Teva Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.12 Otsuka

15.12.1 Company Profile

15.12.2 Main Business and Oncology and Cancer Treatment Drug Information

15.12.3 SWOT Analysis of Otsuka

15.12.4 Otsuka Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.13 Amgen

15.13.1 Company Profile

15.13.2 Main Business and Oncology and Cancer Treatment Drug Information

15.13.3 SWOT Analysis of Amgen

15.13.4 Amgen Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

15.14 Yi Bai Pharmaceutical

15.14.1 Company Profile

15.14.2 Main Business and Oncology and Cancer Treatment Drug Information

15.14.3 SWOT Analysis of Yi Bai Pharmaceutical

15.14.4 Yi Bai Pharmaceutical Oncology and Cancer Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables and Figures

Table Abbreviation and Acronyms

Table Research Scope of Oncology and Cancer Treatment Drug Report

Table Data Sources of Oncology and Cancer Treatment Drug Report

Table Major Assumptions of Oncology and Cancer Treatment Drug Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Oncology and Cancer Treatment Drug Picture

Table Oncology and Cancer Treatment Drug Classification

Table Oncology and Cancer Treatment Drug Applications

Table Drivers of Oncology and Cancer Treatment Drug Market

Table Restraints of Oncology and Cancer Treatment Drug Market

Table Opportunities of Oncology and Cancer Treatment Drug Market

Table Threats of Oncology and Cancer Treatment Drug Market

 Table Covid-19 Impact For Oncology and Cancer Treatment Drug Market

Table Raw Materials Suppliers



Table Different Production Methods of Oncology and Cancer Treatment Drug Table Cost Structure Analysis of Oncology and Cancer Treatment Drug Table Key End Users Table Latest News of Oncology and Cancer Treatment Drug Market Table Merger and Acquisition Table Planned/Future Project of Oncology and Cancer Treatment Drug Market Table Policy of Oncology and Cancer Treatment Drug Market Table 2020-2030 North America Oncology and Cancer Treatment Drug Market Size Figure 2020-2030 North America Oncology and Cancer Treatment Drug Market Size and CAGR Table 2020-2030 North America Oncology and Cancer Treatment Drug Market Size by Application Table 2020-2025 North America Oncology and Cancer Treatment Drug Key Players Revenue Table 2020-2025 North America Oncology and Cancer Treatment Drug Key Players Market Share Table 2020-2030 North America Oncology and Cancer Treatment Drug Market Size by Type Table 2020-2030 United States Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Canada Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Mexico Oncology and Cancer Treatment Drug Market Size Table 2020-2030 South America Oncology and Cancer Treatment Drug Market Size Figure 2020-2030 South America Oncology and Cancer Treatment Drug Market Size and CAGR Table 2020-2030 South America Oncology and Cancer Treatment Drug Market Size by Application Table 2020-2025 South America Oncology and Cancer Treatment Drug Key Players Revenue Table 2020-2025 South America Oncology and Cancer Treatment Drug Key Players Market Share Table 2020-2030 South America Oncology and Cancer Treatment Drug Market Size by Type Table 2020-2030 Brazil Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Argentina Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Chile Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Peru Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Asia & Pacific Oncology and Cancer Treatment Drug Market Size Figure 2020-2030 Asia & Pacific Oncology and Cancer Treatment Drug Market Size and CAGR



Table 2020-2030 Asia & Pacific Oncology and Cancer Treatment Drug Market Size by Application

Table 2020-2025 Asia & Pacific Oncology and Cancer Treatment Drug Key Players Revenue

Table 2020-2025 Asia & Pacific Oncology and Cancer Treatment Drug Key Players Market Share

Table 2020-2030 Asia & Pacific Oncology and Cancer Treatment Drug Market Size by Type

Table 2020-2030 China Oncology and Cancer Treatment Drug Market SizeTable 2020-2030 India Oncology and Cancer Treatment Drug Market Size

Table 2020-2030 Japan Oncology and Cancer Treatment Drug Market Size

Table 2020-2030 South Korea Oncology and Cancer Treatment Drug Market Size

Table 2020-2030 Southeast Asia Oncology and Cancer Treatment Drug Market Size

Table 2020-2030 Australia Oncology and Cancer Treatment Drug Market Size

Table 2020-2030 Europe Oncology and Cancer Treatment Drug Market Size

Figure 2020-2030 Europe Oncology and Cancer Treatment Drug Market Size and CAGR

Table 2020-2030 Europe Oncology and Cancer Treatment Drug Market Size by Application

Table 2020-2025 Europe Oncology and Cancer Treatment Drug Key Players Revenue Table 2020-2025 Europe Oncology and Cancer Treatment Drug Key Players Market Share

Table 2020-2025 MEA Oncology and Cancer Treatment Drug Key Players RevenueTable 2020-2025 MEA Oncology and Cancer Treatment Drug Key Players Market



#### Share

Table 2020-2030 MEA Oncology and Cancer Treatment Drug Market Size by Type Table 2020-2030 Egypt Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Israel Oncology and Cancer Treatment Drug Market Size Table 2020-2030 South Africa Oncology and Cancer Treatment Drug Market Size Table 2020-2030 Gulf Cooperation Council Countries Oncology and Cancer Treatment **Drug Market Size** Table 2020-2030 Turkey Oncology and Cancer Treatment Drug Market Size Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Size by Region Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Size Share by Region Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Size by Application Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Share by Application Table 2020-2025 Global Oncology and Cancer Treatment Drug Key Vendors Revenue Figure 2020-2025 Global Oncology and Cancer Treatment Drug Market Size and Growth Rate Table 2020-2025 Global Oncology and Cancer Treatment Drug Key Vendors Market Share Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Size by Type Table 2020-2025 Global Oncology and Cancer Treatment Drug Market Share by Type Table 2025-2030 Global Oncology and Cancer Treatment Drug Market Size by Region Table 2025-2030 Global Oncology and Cancer Treatment Drug Market Size Share by Region Table 2025-2030 Global Oncology and Cancer Treatment Drug Market Size by Application Table 2025-2030 Global Oncology and Cancer Treatment Drug Market Share by Application Table 2025-2030 Global Oncology and Cancer Treatment Drug Key Vendors Revenue Figure 2025-2030 Global Oncology and Cancer Treatment Drug Market Size and Growth Rate Table 2025-2030 Global Oncology and Cancer Treatment Drug Key Vendors Market Share Table 2025-2030 Global Oncology and Cancer Treatment Drug Market Size by Type Table 2025-2030 Oncology and Cancer Treatment Drug Global Market Share by Type



# I would like to order

Product name: Oncology and Cancer Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

Product link: https://marketpublishers.com/r/O6C2E92E9D9EEN.html

Price: US\$ 3,200.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/O6C2E92E9D9EEN.html</u>